SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Hims & Hers Health, Inc. (HIMS) trades at a trailing P/E of 33.9, forward P/E of 41.6. Trailing earnings yield is 2.95%, forward earnings yield 2.40%. PEG 59.43. Graham Number is $5.50.
Criteria proven by this page:
- VALUE (73/100, Pass) — analyst target implies upside (+40.1%).
- PEG Ratio 59.43 — above 2.0 suggests expensive relative to earnings growth.
- Trailing Earnings Yield 2.95% — below bond yields — investors are paying a premium for expected growth rather than current earnings.
- Analyst consensus target $29.92 (+40.1% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 65/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
73/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — HIMS
Valuation Multiples
P/E (TTM)33.9
Forward P/E41.6
PEG Ratio59.43
Forward PEG59.43
P/B Ratio8.03
P/S Ratio1.79
EV/EBITDA32.6
Per Share Data
EPS (TTM)$0.57
Forward EPS (Est.)$0.51
Book Value / Share$2.38
Revenue / Share$10.34
FCF / Share$0.32
Yields & Fair Value
Earnings Yield2.95%
Forward Earnings Yield2.40%
Dividend Yield0.00%
Graham Number$5.50
SharesGrow IV$97.20 (+355.1%)
Analyst Target$29.92 (+40.1%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2019 |
-4.8 |
0.00 |
-2.54 |
4.17 |
- |
| 2020 |
-28.5 |
0.38 |
-3.51 |
3.47 |
- |
| 2021 |
-11.4 |
-0.83 |
3.66 |
4.50 |
- |
| 2022 |
-20.0 |
0.45 |
4.21 |
2.49 |
- |
| 2023 |
-79.1 |
1.21 |
5.42 |
2.14 |
- |
| 2024 |
41.4 |
-0.07 |
10.95 |
3.54 |
- |
| 2025 |
56.9 |
-33.00 |
13.50 |
3.11 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2019 |
$-2.86 |
$82.56M |
$-72.06M |
-87.3% |
| 2020 |
$-0.51 |
$148.76M |
$-18.11M |
-12.2% |
| 2021 |
$-0.58 |
$271.88M |
$-107.66M |
-39.6% |
| 2022 |
$-0.32 |
$526.92M |
$-65.68M |
-12.5% |
| 2023 |
$-0.11 |
$872M |
$-23.55M |
-2.7% |
| 2024 |
$0.53 |
$1.48B |
$126.04M |
8.5% |
| 2025 |
$0.51 |
$2.35B |
$128.37M |
5.5% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$0.41 |
$0.18 – $0.72 |
$2.76B |
$2.65B – $3.04B |
9 |
| 2027 |
$0.58 |
$0.21 – $0.88 |
$3.31B |
$2.72B – $4.34B |
9 |
| 2028 |
$1.08 |
$0.88 – $1.26 |
$3.92B |
$3.77B – $4.07B |
5 |
| 2029 |
$1.38 |
$1.16 – $1.63 |
$4.73B |
$4.15B – $5.39B |
1 |
| 2030 |
$1.86 |
$1.57 – $2.20 |
$4.63B |
$4.07B – $5.28B |
1 |
